NCT07456228Not yet recruiting
Emergency Stroke Unit With NeuAngio-CT (ESU-ACT)
Effect of Emergency Stroke Unit With NeuAngio-CT Direct for Acute Ischemic Stroke and Suspected Intracranial Large Vessel Occlusion (ESU-ACT)
Source: ClinicalTrials.gov · Last updated 6 Mar 2026
Brief summary (registry, in English)
Rationale: Acute ischemic stroke caused by large-vessel occlusion (LVO) requires rapid recanalization to minimize neurological damage, as shorter onset-to-reperfusion times are strongly associated with better clinical outcomes. Conventional management workflows, which involve separate non-contrast CT or multimodal imaging assessments prior to transfer to the angiography suite, often introduce significant delays. The implementation of a "one-stop" management model using a hybrid sliding-gantry CT/DSA suite allows for immediate diagnosis and subsequent intervention in a single clinical environment, potentially streamlining the transition to treatment. Therefore, the aim of this study is to demonstrate the superiority of the one-stop hybrid suite workflow compared to standard imaging-first management in improving functional outcomes for patients with suspected LVO presenting within 6 hours of symptom onset. Methods and Design: This study is a prospective, multicenter, matched cluster, open-label, blinded endpoint non-randomized cohort. It includes patients aged ≥18 years with a RACE score ≥4, a pre-stroke mRS score ≤1, and suspected intracranial LVO within 6 hours of onset. Hospitals in the exposure group utilize an Emergency Stroke Unit equipped with a sliding NeuAngio-CT/DSA hybrid suite, while control hospitals follow the conventional imaging workflow. Study Outcomes: The primary outcome is the proportion of patients achieving functional independence at 90 days, defined as a modified Rankin Scale (mRS) score of 0-2. The primary safety outcome is the proportion of patients with all-cause mortality at 7 days or at the time of hospital discharge.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 500 (estimated)
- First submitted
- 11 Feb 2026
- Start date
- Mar 2026
- Primary completion date
- Mar 2028
- Lead sponsor
- Beijing Tiantan Hospital
- Diseases
- Stroke
- NCT number
- NCT07456228
What you commit to
- Study type: Observational
- Planned participants: 500
- From Mar 2026 to the primary completion date, Mar 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion Criteria:
- Age ≥ 18 years;
- Clinically diagnosed with acute ischemic stroke;
- RACE score ≥ 4 points upon hospital arrival;
- Time from symptom onset/last known normal to hospital arrival ≤ 6 hours;
- Pre-stroke mRS score 0-1;
- Informed consent signed by the patient or their legal representative.
- Exclusion Criteria:
- Hemorrhagic stroke diagnosed by cranial CT or MRI during this current episode;
- Uncontrolled hypertension with medication (defined as systolic blood pressure \> 185 mmHg or diastolic blood pressure \> 110 mmHg) (Note: Patients may be included if blood pressure can be successfully reduced and maintained at an acceptable level with medication);
- Known hereditary or acquired bleeding tendency, such as coagulation factor deficiency, or INR \> 3.0 or PT \> 3 times the normal range after anticoagulant therapy (Patients without a history of coagulation dysfunction or suspected coagulation dysfunction do not need to wait for laboratory results of INR or prothrombin time before enrollment);
- Received heparin, low-molecular-weight heparin (e.g., dalteparin sodium), or thrombin inhibitors (e.g., bivalirudin, argatroban) within 24 hours with a history of coagulation disorders;
- Baseline laboratory values: blood glucose \< 50 mg/dl (2.78 mmol/L) or \> 400 mg/dl (22.20 mmol/L), hemoglobin count \< 7 mmol/l (11.28 g/dl); platelet count \< 50,000/μl;
- Patients with renal failure, defined as serum creatinine \> 3.0 mg/dl (264 μmol/l) (Note: Patients undergoing dialysis can be included regardless of serum creatinine level);
- Cerebral embolism caused by septic emboli or bacterial endocarditis;
- History of stroke within the past 3 months;
- Seizure at stroke onset leading to diagnostic confusion and difficulty in accurate baseline RACE assessment;
- History of previous neuropsychiatric disorders that make accurate neurological function assessment difficult, such as dementia patients taking cholinesterase inhibitors;
- Diagnosis of cerebral vasculitis, brain tumor, or traumatic brain injury within the past 3 months;
- Major organ surgery or biopsy within 30 days;
- Active bleeding or recent bleeding within 30 days;
- History of previous intracranial stent implantation;
- History of severe contrast agent allergy (non-rash allergy);
- Patients with other contraindications to reperfusion therapy or who refuse reperfusion therapy;
- Life expectancy less than 180 days;
- Lactating women or women with positive pregnancy test on admission;
- Patients who refuse or cannot cooperate with follow-up.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Beijing Tiantan Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.